Home > Boards > US Listed > Medical - Drugs > Cocrystal Pharma Inc. (COCP)

The reaction to the merger is positive, and

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Cocrystal Pharma Provides Update on Influenza A Program GlobeNewswire Inc. - 10/19/2020 8:05:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2020 8:01:03 AM
Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchas... GlobeNewswire Inc. - 8/31/2020 12:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2020 6:01:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/27/2020 6:01:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2020 6:07:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2020 6:02:21 AM
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million GlobeNewswire Inc. - 8/26/2020 10:00:10 PM
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering GlobeNewswire Inc. - 8/26/2020 5:35:29 PM
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs GlobeNewswire Inc. - 8/6/2020 8:05:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 8:01:31 AM
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against... GlobeNewswire Inc. - 8/4/2020 8:05:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 2:34:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/1/2020 4:49:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 6:52:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 6:51:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 6:13:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 4:54:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 4:06:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 4:06:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2020 4:06:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2020 4:31:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 4:15:44 PM
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs GlobeNewswire Inc. - 5/14/2020 7:05:10 AM
investora2z   Wednesday, 11/27/13 11:03:07 AM
Re: None
Post # of 2727 
The reaction to the merger is positive, and the volumes are also good. This is part of the strategic transition announced by Biozone some time back. More details about benefits of the merger with Cocrystal Discovery will emerge over the next few days and weeks. The combined company will initially continue to trade on the OTCBB under the existing symbol of BZNE. The existing shareholders of Biozone and Cocrystal will own approximately 40% and 60% of the combined company respectively, and the merger is expected to close at the end of the year. Cocrystal Discovery is a biotechnology company developing antiviral therapeutics for human diseases. Frost Group and his companies Teva (TEVA) & OPKO (OPK) have earlier made investments in Corcrystal. The PR mentions that the company has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza, the Human Rhinovirus (HRV), Dengue, and the Norovirus. It is targeting two Hepatitis C replication enzymes, with its Polymerase program at lead optimization stage and its Helicase program is at lead identification stage. Dr. Gary Wilcox, the existing CEO and Chairman of Cocrystal, will be the CEO and Chairman of the combined entity. Wilcox expects that the merger will significantly enhance Cocrystal's ability to bring its small molecule inhibitors of the viral replication complex to market. Dr. Frost also expressed confidence about the future of the combined entity due to the quality of the management. Dr. Wilcox has a good track record in the industry. He has served on the Board of Icos Corporation for several years during which Icos was sold to Eli Lilly for $2.3 billion. At Icos, he led the teams which developed Cialis which now has annual sales of $2 billion. Noble Prize winner Dr. Roger Kornberg, Chief Scientist and a Director of Cocrystal Discovery, will be the Chief Scientist of the combined entity.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences